Roflumilast counteracts high-dose dexamethasone-induced steatohepatitis, metabolic abnormalities and aortic injury via inhibiting TNF-α/NF-κB, NLRP3/IL-1β and ER stress sensors
The findings of our study depicted the hepatoprotective and metabolic regulating potentials of ROF in a rat model of DEX- induced steatohepatitis. Thereby, enhancing the overall efficacy and safety of DEX use in management of various disorders.
Authors
- Ghada M. Suddеk (ORCID: https://orcid.org/0000-0002-3283-9471)
- Rania R. Abdеlaziz
- Sara H. Hazem
- M. Aloufi
Institutions
- Mansoura University (EG)
Publication Details
- Journal
- Life Sciences
- Published
- 2025-04-14
- DOI
- https://doi.org/10.1016/j.lfs.2025.123634
- Citations
- 2
- Primary Topic
- Eicosanoids and Hypertension Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 2.22